Lung Cancer

3 Questions to Ask When Being Diagnosed with Lung Cancer

Dr. Bruce Gershenhorn explores 3 questions patients should ask after learning they have lung cancer. Knowledge is power.
November 2018 Volume 4 – Lung Cancer
Bruce Gershenhorn, DO
Medical Oncologist and Medical Director of the Lung Center, Midwestern Regional Medical Center, Cancer Treatment Centers of America (CTCA), Chicago, IL

Few things are more stressful than being told you have lung cancer. Lung cancer is the second most common cancer among Americans, and the first cause of cancer-related deaths in men and women. When hearing they have lung cancer, most people have a sense of urgency to treat the disease, but they often don’t know where to begin.

Recommended For You
Lung Cancer
Early Adjuvant Treatment with Tagrisso Improves Outcomes in Patients with Non–Small-Cell Lung Cancer and EGFR Mutations
By Wayne Kuznar
Treatment with the targeted drug Tagrisso (osimertinib) as an adjuvant therapy (used in addition to primary therapy, such as surgery or chemotherapy) significantly reduces disease recurrence in patients with localized non–small-cell lung cancer (NSCLC) and an EGFR gene mutation (alteration).
Lung Cancer
Zepzelca, New Drug Approved for Metastatic Small-Cell Lung Cancer, Has Fewer Side Effects than Topotecan Chemotherapy
By Chase Doyle
Zepzelca (lurbinectedin), a recently approved drug for patients with metastatic (spreading) small-cell lung cancer, may be even safer than expected, according to data from 2 studies presented at the 2020 ASCO annual meeting.
Lung Cancer
Tecentriq Improves Patient-Reported Outcomes in Advanced Non–Small-Cell Lung Cancer
By Meg Barbor, MPH
Patients with metastatic (spreading to other parts of the body) non–small-cell lung cancer who received the drug Tecentriq (atezolizumab) as a first-line therapy had improvements in physical functioning, without worsening of their lung cancer–related symptoms, compared with patients who received chemotherapy.
Lung Cancer
Imfinzi plus Chemotherapy a New First-Line Option for Patients with Extensive-Stage Small-Cell Lung Cancer
By Phoebe Starr
Patients with extensive-stage small-cell lung cancer, a rare type of lung cancer, now have a new first-line treatment option with Imfinzi (durvalumab), a PD-L1 inhibitor, in combination with chemotherapy, according to new results presented at the 2020 ASCO annual meeting. This new combination has been shown to improve survival for these patients, who do not have many treatment options and whose prognosis (survival outlook) is less than 5 years.
Last modified: June 22, 2020

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.